Autolomous

New advancements at Universitätsklinikum Erlangen bring new possibilities for treating severe lupus nephritis, a critical kidney complication of systemic lupus erythematosus (SLE). A recent case study details the recovery of a 15-year-old patient who, after receiving CD19-targeted CAR T-cell therapy, was freed from hemodialysis and showed significant improvements in kidney function and overall health. This innovative therapy, previously successful in adult patients with refractory SLE, now demonstrates its potential in adolescents. Published in a recent medical journal, this represents a significant step forward in the treatment of autoimmune diseases, showcasing the transformative potential of CAR T-cell therapy for severe lupus nephritis. #AutoimmuneDisease #LupusNephritis #CARTherapy #MedicalResearch #Innovation #UniversityHospitalErlangen

A recent article by Abigail Beaney in Clinical Trials Arena explores the complexities of data collection and sharing in clinical trials. Our CEO, Alexander Seyf, offers valuable insights into the importance of digitization and industry collaboration. "We need to be more open in sharing data – we need to be more collaborative. Right now, the cell and gene therapy industry has such an immense and invaluable opportunity to really start sharing data. The industry is so young, and we can avoid all making the same mistakes as we learn together." Other key takeaways include: 👉 There is a growing debate about the amount of data collection in clinical trials. While more data can be helpful for sponsors to develop new treatments, it can also burden patients and clinical trial sites 👉 Artificial intelligence (AI) is seen as a potential solution for analyzing the large datasets generated in clinical trials. However, the quality and reliability of the data is crucial for AI to be effective 👉 Sharing data across different companies and institutions could be beneficial for accelerating research and development of new treatments At Autolomous, we believe that collaboration is key to unlocking the full potential of cell and gene therapy. By working together across the industry, we can ensure efficient data collection, analysis, and utilization, ultimately leading to faster development of life-saving treatments for more patients. Full article: https://lnkd.in/gn27ycqH #CGT #collaboration #datasharing

Feature - Too much data: a burden or a blessing? Has the data see-saw tipped the other way and are sponsors collecting too much data? The Clinical Trials Arena team spoke to Dr. Michael Murphy M.D., Ph.D., chief medical officer & co-founder, at CRO Worldwide Clinical Trials, Ali Pashazadeh, CEO of Treehill Partners, Catherine Gregor, Chief Clinical Trials officer at Florence Healthcare, Alexander Seyf, CEO of Autolomous and Pina D'Angelo, VP Biometrics at CRO Innovaderm Research Inc. to learn more. - https://lnkd.in/gn27ycqH #clinicaltrials #clinicaldata #clinicaltrialdata #cro #contractresearch

New developments from the University of North Carolina at Chapel Hill School of Medicine bring hope for treating Angelman syndrome, a rare genetic disorder. Ben Philpot, PhD, and his team have discovered a small molecule that can "turn on" the dormant, paternally-inherited UBE3A gene, potentially restoring proper protein and cell function. This significant achievement, published in Nature Communications, represents a major advance in the field and opens new possibilities for innovative gene therapy approaches for Angelman syndrome. #GeneTherapy #UNC #Innovation #AngelmanSyndrome #Research

Following our exciting news about joining the 2024 BioTools Innovator cohort, we're thrilled to share some snippets from the live Innovator Summit event. The discussions were inspiring and invigorating, and the energy amongst the cohort is truly impressive. We're looking forward to continuing to learn, collaborate, and push the boundaries of innovation with these talented individuals and industry leaders throughout the program. Stay tuned for more updates on our progress and the exciting developments from the BioTools Innovator program! In the meantime, you can discover how Autolomous is transforming the biomanufacturing landscape by signing up for autoloMATE® Launchpad, the industry's first free eBR Builder! #innovation #digitization #CGT #BioToolsInnovator

Get ready for an extraordinary event! We're thrilled to share that #BTICapstone24, showcasing 20 of the most promising up-and-coming startups in the life sciences tools space, is scheduled for September 26 in Boston! From groundbreaking innovations and powerful insights to inspiring stories, this Capstone Event is not to be missed. Join the waitlist now and be the first to secure your spot at this exclusive event. Don't miss out on the opportunity to witness the future of life sciences tools and connect with industry leaders. 🔗 https://lnkd.in/eKG2dSPt #LifeSciences #Startups #Innovation #CapstoneEvent #SaveTheDate

What will it take to turn cell and gene therapies into mass-market cures? Could digitisation and AI be the key to improving complex production processes, arduous supply chain, and life-critical logistics? Would more companies be willing to work together on standardisation to provide more flexibility, reduce errors and allow feedback control? We discussed these topics (and more) on a recent podcast episode. Listen to the whole conversation with Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult and Alexander Seyf, Co-founder and CEO of Autolomous on Invent: Life Science hosted by our very own Stuart Lowe: https://lnkd.in/eTANXpXy

Emerging research from the Broad Institute of MIT and Harvard has led to significant advancements in gene-editing technology, enabling efficient insertion of entire genes into human cells. David Liu's lab has developed the eePASSIGE system, which combines prime editing with advanced recombinase enzymes, offering potential therapeutic applications for genetic diseases like cystic fibrosis. This breakthrough, detailed in Nature Biomedical Engineering, marks a major step forward in gene therapy, paving the way for targeted gene integration. #GeneEditing #MIT #Harvard #Innovation #GeneTherapy

Exciting advancements in gene therapy have emerged from Fred Hutch Cancer Center where a foaming liquid formulation developed by bioengineers leads to more effective and cost-efficient gene therapy delivery in mice. Dr. Matthias Stephan's innovative approach offers hope for treating cancers, infectious diseases, and inherited disorders. The foam-based method, published in Nature Communications on May 28, shows potential for treating cancers in confined spaces and autoimmune diseases affecting the digestive system. This breakthrough could make modern medicines more accessible and effective. #GeneTherapy #FredHutch #Innovation #MedicalBreakthrough #Bioengineering #ScienceNews

Join us in supporting Myeloma Cancer Awareness Month inspired by Cancer Research UK (CRUK)'s mission to achieve better outcomes for everyone affected by cancer. This June, we're focusing on raising awareness and empowering informed discussions about myeloma. Early detection is crucial for successful treatment. To empower informed awareness, we've collated clear and accessible information about myeloma cancer, including: 👉 Understanding the basics: A breakdown of what myeloma is 👉 Identifying symptoms: Common signs and changes to watch out for 👉 The future of treatment: Exciting advancements in research & potential new therapies This Myeloma Awareness Month, help educate others! Share this post, and talk to your friends and family. Early detection saves lives! #CancerAwarenessMonth #Myeloma #CRUK